Tele: 561.316.3330
Breaking Medical Device News

Wednesday, October 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

Element Materials Technology (Element) has acquired Nanosyn, a full-service pharmaceuticals contract development and manufacturing organization, significantly strengthening Element’s offering for pharmaceutical and biopharmaceutical customers in North America.

Nanosyn is a leader in drug discovery and small-batch manufacturing of active pharmaceutical ingredients. It has a track record of providing the highest quality services and operates three facilities in the San Francisco Bay Area of approximately 100,000 sq.ft, two of which are FDA registered.

With a team of more than 75 scientists and experts, more than half of whom have a PhD in a scientific discipline, Nanosyn will bolster Element’s breadth of technical services bringing cutting edge innovation and high growth. The team will support pharmaceuticals and biopharmaceuticals customers from early-stage discovery, through clinical trials, formulation, and regulatory approval.

Jo Wetz, Element CEO, said: “This is our fifth acquisition in the life sciences sector this year. Following this growth, it is now the Element Group’s most significant end market, covering pharmaceuticals, medical devices and environmental testing services.

“Nanosyn complements Element’s life sciences offering by extending our services to include drug discovery and small-scale manufacturing for drug development, making us a source of support and true partner for the full value chain. Nanosyn has a deep customer base that includes several of the top pharmaceutical companies in the world, and it supports the development of Element’s position as a full-service solutions provider.”

Nikolai Sepetov PhD, Nanosyn CEO, said: “Joining Element’s global family is a great opportunity for us and will allow our business to leverage its resources and expertise around the world. Nanosyn has a 23 year track record of supporting numerous drug discovery and development programs whichhave led to over fifty clinical candidates and several marketed drugs. We are proud of our strong reputation for continuously providing outstanding services based on cutting edge science. Joining Element as it expands its life sciences offering will create the opportunity for us to be at the forefront of progress and development in the pharmaceutical industry.”

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced...

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

By using this website you agree to accept Medical Device News Magazine Privacy Policy